Researchers at the University of Calgary are developing a new immunotherapy cancer treatment to assist patients when traditional therapies fail [1, 2].
This development provides a critical alternative for patients who no longer respond to standard medical interventions. By targeting the immune system, the therapy aims to offer a path forward for those facing terminal diagnoses after other options are exhausted.
The new treatment is designed for patients when conventional methods, including chemotherapy, radiation, and surgery, are no longer effective [1, 2]. The research team is currently recruiting patients for the next phase of the trial [1, 2].
Past results from the experimental treatment have shown a reduction in rare cancerous tumours [3]. Dr. David Fischer of the University of Calgary said the results for some patients "feels fantastic" [3].
For patients like Kent B., the therapy offered hope after the disease progressed. Kent B. said that when the cancer spread to his lungs, he pondered a lingering, painful descent toward death [3].
Beyond standard oncology, the research has implications for other severe conditions. Recent reports indicate that early immunotherapy may also aid in treating potentially fatal fungal pneumonias [4].
“The therapy aims to offer a path forward for those facing terminal diagnoses after other options are exhausted.”
The shift toward immunotherapy represents a move away from broad-spectrum treatments like chemotherapy toward precision medicine. By recruiting for new trials, the University of Calgary is attempting to bridge the gap for 'refractory' patients—those whose cancers have evolved to resist standard care—potentially expanding the survival window for rare and aggressive tumor types.
